Intuitive Surgical, Inc. amended and restated its bylaws to enhance governance-related disclosures and procedural mechanics for shareholder nominations and proposals. Key changes include aligning with SEC universal proxy rules, refining disclosures for synthetic equity, and establishing new requirements for shareholder-initiated special meetings. The company also updated its voting standard for corporate actions to a majority of votes cast. Intuitive Surgical, Inc. develops and manufactures robotic-assisted surgical systems and instruments.

Intuitive Surgical, Inc. reported second quarter 2026 financial results, with revenue of $2.89 billion, a 19% increase compared to the second quarter of 2025. GAAP net income attributable to the company was $818 million, or $2.29 per diluted share, while non-GAAP net income was $1.00 billion, or $s2.80 per share. Worldwide procedure volume grew approximately 16%, driven by da Vinci and Ion systems. The company repurchased 0.9 million shares of its common stock for $0.38 billion in the quarter. Intuitive Surgical, Inc. is a global technology leader in minimally invasive care and robotic-assisted surgery.

Effective July 1, 2026, Henry L. Charlton will transition from his role as Chief Commercial and Marketing Officer at Intuitive Surgical, Inc. to serve as Senior Vice President of Global Business Operations. Taylor Patton will succeed Mr. Charlton as the company's new Chief Commercial and Marketing Officer.

Intuitive Surgical, Inc. stockholders approved an amended 2010 Incentive Award Plan that increases the common stock reserve to 125,350,000 shares. Additionally, the company's Board increased the authorized amount for its common stock repurchase program to an aggregate of $5.0 billion.

Intuitive Surgical, Inc. completed the acquisition of the da Vinci and Ion distribution business, operated by ab medica, Abex, Excelencia Robótica, and their affiliates, on March 1, 2026. The company announced the closing of the transaction through a press release issued on March 2, 2026.